Vision-restoration company Science Corp has closed a US$230m Series C financing round which will allow it to complete the commercialisation of its brain-computer interface, retinal implant, known as PRIMA.
The deal, which was oversubscribed, secured participation from pre-existing investors Khosla Ventures, Lightspeed Venture Partners, Y Combinator, IQT, and Quiet Capital amongst others.
It raised the total capital invested into the company to approximately $490m since it was founded in 2021.
The company says the new investment will enable it to fully see through the commercialisation of PRIMA, as well as ‘advancing its other core pipeline programs into the clinic’.
In clinical trials, PRIMA has successfully restored vision to patients blinded by late-stage macular degeneration.
Results from this European clinical trial demonstrated that the implant could restore functional central vision, effectively working as artificial photoreceptors in the retina.
Following the successful trial the California-based company has submitted a CE mark application to the European Union, as well as applying to the US Food and Drug Administration for regulatory approval.
Max Hodak, co-founder and CEO of Science Corp, said: “There is a profound sense in which the brain is the ultimate central object of medicine: it is the only organ which is not, even in principle, transplantable, and it’s becoming increasingly clear that engaging with it directly as an information processing system facilitates extraordinary effect sizes.”
Darius Shahida, Science Corp’s Chief Strategy Officer, added: “The strength and calibre of this syndicate reflects both the urgency of the problems we are addressing and the credibility of our execution so far.”
Alzheimer’s in focus
The company is now expanding its PRIMA clinical trial program to include other retinal diseases, such as Stargardt disease and retinitis pigmentosa.
Alzheimer-treatment focused US company Cognito Therapeutics has successfully completed a US $105M Series C round led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital, with further investment from New Vintage, Apollo Health Ventures, Benvolio Group and others.
The new financing will allow the Massachusetts company to advance toward a regulatory submission, and commercial launch, while supporting continued clinical development of its Spectris platform, ahead of its anticipated market entry in 2027.
Christian Howell, Chief Executive Officer, Cognito Therapeutics, said: “With this financing, we are entering a pivotal moment for our company, and for the patients and families waiting for new options in Alzheimer’s disease.
“Spectris has the potential to become the world’s first physician-prescribed, at-home neuro-protective therapy for patients diagnosed with Alzheimer’s, designed to preserve cognition and daily function. This funding allows us to make this therapy accessible to those who need it most.”
Spectris is an investigational physician-prescribed, at-home therapeutic platform designed to evoke coordinated neural activity, across interconnected networks, through non-invasive visual and auditory stimulation.
By engaging neural network function through the brain’s natural sensory pathways, Spectris is being studied for its potential to preserve cognition, daily function, and brain structure in patients diagnosed with Alzheimer’s disease.
US$50m sleep boost
US business Eight Sleep has secured an additional US $50m just a few months after raising US$100in in August last year.
Founded in 2014, Eight Sleep brands itself as a ‘sleep technology’ company that combines technology, physiology and data ‘to unlock deeper sleep and better health’.
In 2025 the business achieved free cash-flow positivity and launched three new products: Pod 5, Pod Pillow Cover and Thermal Blanket.
The new capital will fund its expansion from sleep optimisation into ‘predictive, AI-driven health’, it says.
“Sleep was just the beginning,” said Matteo Franceschetti, co-founder and CEO of Eight Sleep, in a release. “We’ve built the most advanced AI-powered health sensing system in the world – one that learns your body better every night and acts on that knowledge.
“This investment gives us the resources to take that intelligence beyond the bedroom and into every dimension of personal health. … Our goal is to build the defining health technology company of this generation.”
The company started out selling a smart mattress, or Pod, that uses embedded sensors to collect data to study trends about how people sleep.
At the time of last year’s raise the company was valued at US$1bn.
Swiss wearable boost
Xsensio SA, a Swiss tech company pioneering continuous biochemical monitoring, has successfully closed a US$7m, oversubscribed, Series A financing round.
The round was led by San Francisco-based venture capital firm WI Harper, with participation from Privilège Ventures, the European Innovation Council, and private investors across the United States, Europe, and Asia.
Its Lab-on-Skin wearable biosensing platform aims to ‘deliver continuous, real-time biochemical information for personalised and preventive healthcare’.
The new funding will enable Xsensio to accelerate the development and clinical validation of its Lab-on-Skin wearable biosensing platform, designed to provide dynamic, multi-modal, biochemical information to support clinical decision-making in the hospital and beyond.
“This Series A marks a pivotal step in translating continuous biochemical monitoring into real clinical environments,” said Esmeralda Megally, CEO of Xsensio.
“For the first time, clinicians can access key continuous biochemical data in real time, information that has historically been unavailable at the point of care. This capability has the potential to fundamentally improve how patients are monitored and treated.”
Xsensio has also signed a long-term collaboration with Texas Instruments, a global leader in semiconductor technology. Xsensio was recognised by TIME as one of the World’s Top HealthTech Companies in 2025.
Paris-based Gleamer, one of Europe’s fastest-growing AI radiology platforms, has been acquired by US imaging giant RadNet in a deal valued at €230m.
The French medtech, which was founded in 2017 by Christian Allouche, Dr Alexis Ducarouge, and Dr Nor-eddine Regnard, uses AI to reduce radiology misdiagnoses.
By the end of 2025, Gleamer had reached around €30m in annual recurring revenue and built a customer base of roughly 700 clients across 44 countries.
Since its inception it has raised around €50m across three funding rounds: €27M in 2023, €7.5M in 2020, and €1.1M in 2018.